Company: INKT
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061041
Chunk: 19

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 19
---
 |
| Strategic Consultant and Scientific Advisory Board Member; Former Chief Scientific Officer |     | 2023 |      |     |        | 333,989 |     |        | 119,070 |     |        |    39,926 |     |        |  26,550 |     |              | 49,294 |     |       |   568,829 |
| Christine M. Klaskin (3)                                                                   |     | 2024 |      |     |        |  29,822 |     |        |       - |     |        |         - |     |        |       - |     |              |      - |     |       |    29,822 |
| Treasurer                                                                                  |     | 2023 |      |     |        |  29,624 |     |        |       - |     |        |         - |     |        |       - |     |              |      - |     |       |    29,624 |

(1) Dr. Buell also serves as Chairman of Agenus' Executive Council. (2) Dr. van Dijk was appointed as our Chief Scientific Officer effective March 2, 2022 and resigned from such position effective November 15, 2024. Dr. van Dijk continues to serve as a strategic consultant to us and a member of our Scientific Advisory Board. Compensation amounts for Dr. van Dijk were paid in British pounds and have been converted to U.S. dollars for purposes of the table. The U.S. dollar per British pound exchange rates used for such conversions were 1.28 and 1.24 for 2024 and 2023, respectively. (3) Ms. Klaskin is also Vice President, Finance of Agenus. (4) The amounts reported in this column for Ms. Klaskin reflect the portion of compensation from Agenus that was allocated to the services Ms. Klaskin provided to the Company for the applicable fiscal year. Ms. Klaskin does not receive any compensation directly from the Company for her services to the Company. (5) The amounts reported reflect annual incentive bonuses for the applicable year. Our Compensation Committee has postponed the review of annual incentive bonuses for 2024, and we have not yet determined the annual incentive bonuses, if any, that will be payable to our named executive officers. We expect that bonus amounts for 2024 will be determined in June 2025. For 2023